Biotage AB (publ) – disclosure notice of substantial holding of shares

Biotage AB (publ) has as of 13 June 2013 bought back an aggregate of 3,574,007
shares under the re-purchase program resolved at the Annual General Meeting with
the shareholders on 25 April 2013. The Company`s aggregated holding of own
shares corresponds to 5.11 per cent of the total amount of shares and votes in
the Company.

The total amount of shares outstanding, including shares held in treasury,
amounts to 69,861,330.

The Board of Directors intends to propose the forthcoming Annual General Meeting
to resolve that the re-purchased shares shall be cancelled.

Biotage discloses the information provided herein pursuant to the Swedish
Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The
information was submitted for publication at 09.00 on June 14 2013.

Contact:
Torben Jörgensen, President and CEO
Tel: +46 707 49 05 84, torben.jorgensen@biotage.com

About Biotage
Biotage offers solutions, knowledge and experience in the areas of analytical
chemistry, medicinal chemistry, separation and purification. The customers
include pharmaceutical and biotech companies, companies within the food industry
and leading academic institutes. The company is headquartered in Uppsala and has
offices in the US, UK, China and Japan. Biotage has approx. 290 employees and
had sales of 463 MSEK in 2012. Biotage is listed on the NASDAQ OMX Nordic
Stockholm stock exchange. Website: www.biotage.com